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Ulcerative colitis and Crohn’s disease are the most common forms of inflammatory bowel disease (IBD), both of 
unknown aetiology. These conditions are characterised by the chronic and recurrent inflammation of different parts 
of the gastrointestinal tract, but while in CD, chronic inflammation may affect any part of the gastrointestinal tract, 
in UC, mucosal inflammatory changes are confined to the colon. IBD is currently on the increase, and it is important 
for the dental professional to be familiar with the condition as patients with IBD may present oral manifestations of 
the underlying disease. Such manifestations of IBD may precede the onset of intestinal radiographic lesions by as 
much as a year, or even more. Treatments used to manage IBD can affect the delivery of routine dental care.
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Introduction
Inflammatory bowel diseases (IBD) include Crohn’s 
disease (CD), ulcerative colitis (UC) and an ill-defined 
group of medical conditions known as indeterminate 
colitis. These are characterised by the chronic and recu-
rrent inflammation of different parts of the gastrointes-
tinal tract (1).
In CD, chronic inflammation may affect any part of the 
gastrointestinal tract, whereas in UC, mucosal infla-
mmatory changes are confined to the colon (1,2). The 
term indeterminate colitis should be reserved only for 
those cases where colectomy has been performed and 
pathologists are unable to make a definitive diagnosis 
of either CD or UC after full examination, and the term 
IBD type unclassified is suggested for patients in whom 
there is clinical and endoscopic evidence of chronic IBD 
affecting the colon, without small bowel involvement, 
and with no definitive histological or other evidence to 
favour either CD or UC (3).
The aetiology of IBD is unknown: it hasn’t been esta-
blished if there is a cause and effect relationship with a 
single agent that causes the disease’s characteristics, or 
whether inherited molecular alterations are responsible.
The currently more accepted etiopathogenic theory su-
ggests that the intestinal inflammation is a consequence 
of an abnormal action of T lymphocytes upon the enteri-
cal bacterial flora in a genetically susceptible individual 
(4).
The onset of the disease occurs more often in the second 
or the third decade of life, but there also is another peak 
in the 60s (5), without a clear predominance of gender 
(4).
The incidence, and consequently the prevalence, of IBD 
has been increasing of late. The prevalence of IBD is 1 
in 10,000 people.
It is important for the dental professional to be familiar 
with the condition as patients with IBD may present oral 
manifestations of the underlying disease. Such manifes-
tations of IBD may precede the onset of intestinal ra-
diographic lesions by as much as a year, or even more. 
Treatments used to manage IBD can affect the delivery 
of routine dental care. (6).
Objectives
The aim of this article is to carry out a review of literatu-
re about IBD, and to examine the latest research concer-
ning the oral manifestations and dental management of 
patients with this condition.
Material and methods
The subject-related research was carried out on the Pub-
med-Medline database. As a research strategy we used 
different combinations of the following keywords: in-
flammatory bowel disease, Crohn’s disease, ulcerative 
colitis, oral manifestations, oral complications, dental 
management, pyostomatitis vegetans.
We included articles published in both English and Spa-
nish from 1999. We reviewed 17 articles. 
Results
Ulcerative colitis (UC)
UC is an inflammatory disease of the bowel affecting 
the superficial lining mucosa in the rectum and the large 
intestine. The disease typically starts from the rectum 
and continues through the large bowel sparing the dee-
per layers of the intestinal wall. The small intestine is 
rarely affected (1).
Upon endoscopic examination of patients with UC, the 
intestinal mucosa presents friability, erythema, ulcera-
tions, and pseudopolyps. Histological samples reveal 
significant lymphocytic infiltration of lamina propria, 
fine granularity, cryptic inflammation, and abscess (5).
Based on the extent of colonic involvement, UC can be 
classified into:
- ulcerative proctitis, when involvement is limited to the 
rectum
- left sided UC, when involvement is limited to a por-
tion of the colorectum distal to the splenic flexure,
- extensive UC, when involvement extends proximal to 
the splenic flexure (3).
Signs and symptoms often worsen with withdrawal of 
feeding and include abdominal pain and distension, chro-
nic diarrhea mixed with blood or mucous, weight loss, 
and fatigue (5). Mortality from UC is not significant, but 
the chronicity and periodic flare-ups, disease complica-
tions, as well as the cost and side effects of therapy, pose 
significant morbidity in those affected. Resection of co-
lon often cures all systemic signs and symptoms, which 
may suggest the disease process is confined to the colon 
rather than involving the general immune system (1).
Crohn’s disease
CD is a chronic, transmural inflammatory bowel disease 
that may affect any part of the bowel system including 
the oral cavity (1,2). In contrast to ulcerative colitis, CD 
has a patchy rather than continuous distribution throug-
hout the gut and is transmural with inflammation exten-
ding the entire thickness of the intestinal wall (1).
Upon endoscopic examination of patients with CD, the 
diseased intestinal mucosa may present mucosal edema, 
thickening, obvious ulceration, cobblestoning, and pseu-
dopolyps. Histological features of CD include infiltra-
tion of intestinal mucosa with neutrophils, lymphocytes, 
and mononuclear cells (5). Clusters of giant cells or non-
caseating granulomas have been found in up to 60% of 
the cases (1).
Based on the bowel segment it affects, CD has been clas-
sified into:
- L1 ileitis, affecting ileum only, 
- L2 colitis, affecting colon only,
- L3 ileocolic affecting both ileum and colon (1,3)
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- L4 upper, isolated upper disease (3).
Signs and symptoms of CD are variable and include 
abdominal cramps, diarrhea, melena, rectal bleeding, 
vomiting, poor appetite, fatigue and weight loss. The 
long-term progression of CD is unpredictable. Whereas 
in some patients, only the inflammatory component of 
the disease manifests, others may develop complications 
(1).
Table 1 provides a comparison summary of CD and 
CU. 
The medical management of IBD includes the following 
(6):
- Antidiarrheal/antispasmodic agents (diphenoxylate 
and atropine),
- Anti-inflammatory agents (sulfasalazine or 5-amino-
salicylates),
- Antibiotics (metronidazole),
- Corticosteroids (topical by enema and/or systemic),
Immunosuppressants (azothiaprine, 6-mercaptopuri-
ne).
Surgical intervention or colectomy is reserved for recal-
citrant, severe cases of UC with significant hemorrhage, 
toxic megacolon, or perforation, and often brings about 
a cure.
Oral manifestations of patient with IBD
The clinical distinction between the oral manifestations 
of Crohn’s disease and ulcerative colitis may be blurred 
with overlapping clinical features (7).
Ulcerative colitis• 
Mucosal changes of UC in the oral cavity include stoma-
titis, glossitis, cheilitis, aphthous ulceration, and pyosto-
matitis vegetans (1), which represents a specific marker 
of ulcerative colitis even if the nature of this association 
is not clear (8).
Erosive temporo-mandibular joint disease secondary to 
ulcerative colitis-associated spondyloarthropathy, has 
also been reported (7,9).
Crohn’s disease• 
Mucocutaneous changes of CD in the orofacial region 
include granulomatous changes of oral CD caused by 
direct extension of intestinal inflammation, or those of 
metastatic CD affecting a distant cutaneous site noncon-
tiguous with the bowel. The prevalence of oral CD varies 
between 0,5 and 80,0% and oral findings may precede 
onset of intestinal disease in up to 60% patients (1,10). 
Clinical manifestations of oral CD include specific and 
non-specific changes. Changes considered specific and 
pathogonomic for CD are cheilitis granulomatosa, co-
bblestoning of oral mucosa, mucosal tags and linear 
ulcerations, and hyperplastic folds of buccal vestibu-
les (1,2,11). Non-specific changes are angular cheilitis, 
aphthous stomatitis and pyostomatitis vegetans (1). 
Dental erosion, halitosis, odynophagia, dysphagia, high 
prevalence of caries, granulomatous and autoimmune-
like changes in minor salivary glands, and reduced sali-
vation have also been reported (12).
Table 2 provides a summary of specific and nonspecific 
changes associated with IBD.
Orofacial granulomatosis
Crohn’s disease Ulcerative colitis














Superficial lining mucosa inflammation
Rare presence of fistulae and stenotic complication




Table 1. Differences between Crohn’s disease and ulcerative colitis.













Table 2. Oral lesions in IBD (11).
Oral granulomatosis is a common manifestation in pa-
tients with IBD and is typified by recurrent or persistent 
swelling of the lips, cheeks, gingivae, or oral mucosa 
with characteristic noncaseating granulomas on histo-
logic examination (11). The lips are the most frequent 
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site of involvement; the labial tissues demonstrate a non-
tender, persistent swelling that may involve one or both 
lips (13). Many patients with orofacial granulomatosis 
do eventually develop gastrointestinal disease consistent 
with Crohn’s disease (11).
Cobblestoning mucosa and mucosal tags
Cobblestoning refers to nodular granulomatous swe-
llings that result in a cobblestone appearance of the oral 
mucosa, particularly on the labial and buccal mucosa. 
Along with mucosal tags, cobblestoning is highly sug-
gestive of CD (11).
Deep linear ulcers with hyperplastic folds
They are specifically associated with IBD (11). These 
ulcerations may cause pain on touch, or when eating 
acidic, spicy or hot foods. These ulcers, which are typi-
cally persistent, linear and deep, should not be confused 
with aphthous ulcers, which are shallow, round to oval 
shaped lesions that heal spontaneously in approximately 
seven to 14 days (7).
Pyostomatitis vegetans
Although IBD may precede the onset of oral or cuta-
neous lesions by months or years, sometimes the symp-
toms may be minimal and not sufficient to make an early 
diagnosis. In these cases the identification of PV could 
represent a reason to encourage diagnostic investigations 
intended to reveal subclinical intestinal diseases (8).
Clinically PV is characterised by multiple pustules on 
an erythematous base. The friable pustules have a grey 
to yellow necrotic appearance; they erode and form sha-
llow ‘snail-track’ ulcers which may affect all areas of 
oral mucosa, although the most commonly affected sites 
are the labial and buccal mucosae, hard and soft pala-
te, gingivae and sulci, while the least affected sites are 
the tongue and floor of mouth. Vegetations in areas of 
erythema can be seen especially on the gingivae and pa-
late. As vegetating lesions progress the mucosa may be 
thrown into verrucous folds, particularly the lesions of 
buccal and labial mucosae which are soft and oedema-
tous. Pain is not prominent even when there is extensive 
oral involvement (14).
Microscopically, the lesions mimic the crypt abscesses 
of colonic lesions, without evidence of granulomatous 
inflammation. The oral submucosa shows edema with 
neutrophils, eosinophils and lymphocytes, while the epi-
thelium shows spongiosis with neutrophilic and eosino-
philic abscesses.
The primary objective in the treatment of PV must be 
identifying and/or controlling the associated bowel di-
sease. Lesions frequently improve when the colitis is 
controlled; likewise, an exacerbation of colitis usually is 
followed by a similar flare in oral lesions. 
Oral lesions are often treated effectively with topi-
cal corticosteroids in a gel or mouthwash formulation. 
However, systemic corticosteroids, dapsone and other 
immunosuppressive therapy may be suggested for mo-
derate-to-severe symptomatic lesions in the oral cavity 
that are recalcitrant to topical therapy (15).
Aphthous ulcers
Aphthous ulcers are considered by many to be non-spe-
cific, as they can be seen in up to 20% of the general 
population; however aphtae are usually more extensive 
and persistent when associated with IBD (11). If a pa-
tient develops IBD during adulthood but has a history 
of recurrent aphthous ulcerations since adolescence, it 
is likely that the aphthous ulcers represent a coincident 
process that may be exacerbated by IBD or its manage-
ment. For example, anti-inflammatory medications such 
as 5-aminosalicylates, the mainstay of IBD treatment, 
are excreted in saliva and are known to cause aphthous 
ulcers in some patients (6).
Aphthous ulcerations are a primary component of Be-
hçet syndrome, which has also been implicated in in-
flammation of the large bowel (6), and also of Sweet’s 
syndrome, which is a rare cutaneous manifestation of 
ulcerative colitis or Crohn’s disease (16). In the past, it 
was believed that the association between an uncommon 
disorder like Sweet’s syndrome and a relatively com-
mon disease like IBD was coincidental, but given the 
increasing number of case reports on Sweet’s syndrome 
and IBD (IBD is now the third most common disease 
associated with Sweet’s syndrome) (17), this is unlikely. 
The other factor supporting a true association between 
Sweet’s syndrome and IBD is that Sweet’s syndrome is 
from the same family of cutaneous disorders as erythe-
ma nodosum and pyoderma gangrenosum, suggesting a 
possible common pathogenesis (16). 
Other associations
It is difficult to determine which oral manifestations are 
expressions of IBD, which represent preexisting and/
or coincidental findings, and which result directly from 
medical treatment of bowel disease.
Although candidosis is often associated with IBD pa-
tients, it probably represents either a reaction to the bac-
teriostatic effect of sulfasalazine or an impaired ability of 
neutrophils to kill this granuloma provoking organism, 
rather than a primary manifestation of the disorder. 
Likewise, some anti-inflammatory and sulfa-containing 
preparations used to manage IBD patients are reported 
to cause lichenoid drug reactions (6).
Dental management of patients with IBD
Patients with IBD are at increased risk of developing 
dental caries and oral infections. The causes of the in-
creased incidence are multiple, but they appear to be re-
lated to either the patient’s altered immune status or to 
diet. It is also important to recognise the risk of adrenal 
gland suppression in patients receiving corticosteroids 
to manage their IBD. It may be necessary to augment 
the steroid regimen during some dental treatments, es-
pecially for anxious patients in whom preoperative or 
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postoperative pain management is difficult or when a 
complicated or stressful procedure is anticipated.
Oral inflammatory and granulomatous lesions associa-
ted with IBD may respond to topical steroid therapy but 
should not be used indefinitely due to the risk of mucosal 
atrophy and systemic absorption (6).
Dental management of patients with IBD should include 
the following:
Frequent preventive and routine dental care to pre-• 
vent destruction of hard and soft tissue.
Evaluation of hypothalamic/pituitary/adrenal cor-• 
tical function to determine the patient’s ability to 
undergo extensive dental procedures.
Avoid prescribing non-steroidal anti-inflammatory • 
drugs (NSAID), as they can trigger a flare-up. The 
use of paracetamol is recommended, although it can 
also adversely affect patients.
Early diagnosis and treatment of oral infections to • 
enhance the gastroenterologist’s ability to manage 
the IBD.
Diagnosis (biopsy if necessary) and treatment of • 
oral inflammatory, infectious, or granulomatous 
oral lesions (6).
Conclusions
Mucosal changes of UC in the oral cavity include stoma-
titis, glossitis, cheilitis, aphtous ulcerations, and pyosto-
matitis vegetans. The latter represents a specific marker 
of ulcerative colitis (8).
Macrocheilia, cobblestoning of oral mucosa, deep li-
near ulcers of buccal vestibules, and polypoid mucosal 
tags are considered specific and pathogonomic for CD 
(1,2,11). Nonspecific changes include angular cheilitis, 
aphthous stomatitis and pyostomatitis vegetans (1).
In dental treatment of patients with IBD, it is important 
that they undergo frequent dental revisions and preven-
tive care to avoid oral infections and hard and soft tissue 
destruction; it is also important to diagnose and treat all 
inflammatory, infectious or granulomatous oral lesions. 
We also have to avoid NSAID prescriptions and evalua-
te hypothalamic/pituitary/adrenal cortical functions.
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